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AbstrACt
Introduction Fever commonly leads to healthcare 
seeking and hospital admission in sub- Saharan Africa 
and Asia. There is only limited guidance for clinicians 
managing non- malarial fevers, which often results in 
inappropriate treatment for patients. Furthermore, there is 
little evidence for estimates of disease burden, or to guide 
empirical therapy, control measures, resource allocation, 
prioritisation of clinical diagnostics or antimicrobial 
stewardship. The Febrile Illness Evaluation in a Broad 
Range of Endemicities (FIEBRE) study seeks to address 
these information gaps.
Methods and analysis FIEBRE investigates febrile 
illness in paediatric and adult outpatients and inpatients 
using standardised clinical, laboratory and social science 
protocols over a minimum 12- month period at five sites 
in sub- Saharan Africa and Southeastern and Southern 
Asia. Patients presenting with fever are enrolled and 
provide clinical data, pharyngeal swabs and a venous 
blood sample; selected participants also provide a urine 
sample. Laboratory assessments target infections that 
are treatable and/or preventable. Selected point- of- care 
tests, as well as blood and urine cultures and antimicrobial 
susceptibility testing, are performed on site. On day 
28, patients provide a second venous blood sample for 
serology and information on clinical outcome. Further 
diagnostic assays are performed at international reference 
laboratories. Blood and pharyngeal samples from matched 
community controls enable calculation of AFs, and surveys 
of treatment seeking allow estimation of the incidence 
of common infections. Additional assays detect markers 
that may differentiate bacterial from non- bacterial causes 
of illness and/or prognosticate illness severity. Social 
science research on antimicrobial use will inform future 
recommendations for fever case management. Residual 
samples from participants are stored for future use.
Ethics and dissemination Ethics approval was obtained 
from all relevant institutional and national committees; 
written informed consent is obtained from all participants 
or parents/guardians. Final results will be shared with 
participating communities, and in open- access journals 
and other scientific fora. Study documents are available 
online (https:// doi. org/ 10. 17037/ PUBS. 04652739).
IntroduCtIon
Fever is one of the most common symptoms 
leading to healthcare seeking and hospital 
admission in sub- Saharan Africa and Asia.1 2 
Current age- specific WHO algorithms for the 
primary care level provide only limited guid-
ance to clinicians for the management of 
non- malarial fevers. If the malaria test is 
negative, the patient is classified as ‘fever: 
no malaria’ in the Integrated Management 
of Childhood Illness guidelines3 or in the 
Integrated Management of Adolescent and 
Adult Illness guidelines,4 and advice is given 
to ‘treat according to the apparent cause of 
fever.’ Many febrile illnesses present with 
strengths and limitations of this study
 ► Harmonised protocol at multiple sites to allow com-
parison of results across diverse epidemiological, 
geographic and cultural settings.
 ► Collection of data from inpatients, outpatients and 
community controls of all ages ≥2 months, at mul-
tiple sites across Africa and Asia, over the course 
of >12 months at each site to capture seasonal 
variation.
 ► Inclusion of a control group at each site to aid attri-
bution and to allow estimation of disease incidence.
 ► Standardised diagnostic testing at pathogen- 
specific reference laboratories according to interna-
tionally accepted clinical case definitions.
 ► Current study limited to only five sites; protocol and 
supporting documents are freely available to other 
researchers who may wish to undertake similar 
work.
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non- specific symptoms and signs, and the current recom-
mendations often result in treatable diseases being left 
untreated or treated with inappropriate antimicrobials 
on the one hand and overtreatment of self- limiting condi-
tions with antimicrobials on the other, with important 
implications for the development of antimicrobial resis-
tance.5 6
Little is currently known about the causes of fever 
in many low- income and middle- income countries 
(LMICs),7–9 so there is sparse evidence on which to base 
empirical treatment guidelines for febrile patients, espe-
cially in more remote areas. Some studies provide an 
indication of the clinical spectrum of febrile illness,10 11 
but these studies were often disease specific, for example, 
focussing on urinary tract infections in Nigeria12 or arbo-
viruses in Asia.13 A few studies designed to look at aeti-
ologies of fever in given locations have been published 
recently.2 14–17 While the results are useful within the 
specific study areas, the epidemiology of infections varies 
in place and time, so the generalisability of single- site 
studies is uncertain. Furthermore, the study approaches 
were heterogeneous—with differences in patient age, 
type of health facility, seasons covered, inclusion criteria, 
study design, sampling techniques and pathology tests 
employed—making it difficult to compare findings across 
sites and to produce a clear picture of the most common 
causes of fever in each geographical setting, age group 
and at each level of care. In addition, there is disabling 
heterogeneity in eligibility criteria, case definitions, 
use of diagnostic tests that are not sufficiently validated 
or standardised and lack of control groups, preventing 
calculation of attributable fractions (AFs). Recently, two 
multisite, prospective, case–control studies demonstrated 
the potential of using harmonised research protocols with 
standardised diagnostic methods to investigate the causes 
of clinical syndromes with high morbidity and mortality in 
resource- limited settings: the Global Enteric Multicenter 
Study18 and the Pneumonia Aetiology Research for Child 
Health study19 determined the predominant infectious 
causes of diarrhoea and pneumonia, respectively, among 
children in multiple African and Asian countries.
Improved diagnosis and treatment of febrile illness 
matter both for the care of individual patients and for 
public health goals. Besides data gaps on prevalence of 
specific infections in febrile patients, there is very little 
information on incidence for many of the infections 
thought to be clinically important in Africa and Asia. 
Consequently, there is little information on which to 
base estimates of burden of disease or to guide empir-
ical therapy, control measures and resource allocation.20 
In addition, the ability to differentiate between bacterial 
and viral infections and between broad groups of bacte-
rial pathogens based on antimicrobial susceptibility, 
could have a major global impact on antimicrobial resis-
tance by limiting the unnecessary use of antimicrobials. 
However, there are limited data on antimicrobial usage 
and how and why the frequency and appropriateness of 
usage vary across LMICs. There is increasing emphasis 
on identification and incorporation into point- of- care 
diagnostic tests of markers of immune and endothelial 
activation (hereafter ‘biomarkers’) that can distinguish 
between bacterial causes of fever requiring antimicrobial 
treatment and viral or self- limiting infections,21 or that 
can identify current or incipient severe illness.22 23
The Febrile Illness Evaluation in a Broad Range of 
Endemicities (FIEBRE) study has been designed to help 
address these information gaps. FIEBRE is a multisite 
investigation in paediatric and adult outpatients and 
inpatients, using standardised clinical, reference labora-
tory and social science protocols, in low- resource regions 
from which few or no data are available. FIEBRE is being 
conducted at five sites in sub- Saharan Africa and South-
eastern and Southern Asia, and the full protocol, data 
collection forms, standard operating procedures and 
other supplementary information are freely available to 
researchers who may wish to conduct harmonised work 
at other sites (accessible on the FIEBRE study website 
(https:// doi. org/ 10. 17037/ PUBS. 04652739) or from 
coinvestigators). This paper describes the clinical, epide-
miological and laboratory activities of FIEBRE, which 
seek to identify infections that are treatable (eg, with 
specific antimicrobials) and/or preventable (eg, with 
vaccination or vector- control approaches), to document 
antimicrobial susceptibility in isolated micro- organisms 
and to evaluate biomarkers that may be useful in distin-
guishing bacterial from other causes of fever and/or in 
prognosis. An overview of the social science work and its 
relationship to the broader study is also provided, with 
country- specific protocols available on the FIEBRE study 
website (https:// doi. org/ 10. 17037/ PUBS. 04652739).
MEthods And AnAlysIs
study design
FIEBRE is a study of febrile illness in people aged 2 months 
and older residing at one of five sites (three sites in sub- 
Saharan Africa, one in Southeastern and one in Southern 
Asia). The study’s specific objectives are listed in box 1. 
Patients who present with fever at the selected facilities 
are recruited (day 0) if they or their guardians/caregivers 
(in the case of minors or unconscious patients) provide 
written informed consent. Study staff take a targeted illness 
and exposure history and perform a physical examina-
tion. Nasopharyngeal and/or oropharyngeal swabs and a 
venous blood sample are collected from all participants; a 
urine sample is collected from selected participants. Tests 
for malaria and for HIV (at sites where HIV prevalence 
exceeds 1% in the general adult population, for patients 
not already known to be infected), serum cryptococcal 
antigen (CrAg) and urinary lipoarabinomannan (uLAM) 
detection, and blood and urine cultures are performed 
on site; bacteria and fungi isolated from clinical speci-
mens are identified and tested for antimicrobial suscepti-
bility. At day 28 after enrolment, study patients are asked 
to provide a further venous blood sample for serology, 
and clinical outcome is evaluated.
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box 1 specific objectives of Febrile Illness Evaluation in a 
broad range of Endemicities
Primary objectives
1. To determine the treatable and/or preventable causes of fever in 
children aged ≥2 months and in adults presenting as outpatients, 
and among those admitted to hospitals, in areas represented by the 
study sites.
2. To determine how fever aetiology varies according to patient age, 
geographical area, local malaria and HIV prevalence, and other risk 
factors.
3. To determine the prevalence and spectrum of antimicrobial resist-
ance among bacterial pathogens identified in clinical specimens 
from febrile patients.
Secondary objectives
1. To generate data on incidence of specific infections in study site 
catchment areas and therefore contribute key data on disease bur-
den for some infections that are not counted in current global bur-
den of disease estimates.
2. To build an archive of well- characterised and geographically diverse 
biological samples from patients with well- characterised clinical 
phenotypes, and from community controls, for use in evaluation of 
new diagnostic and prognostic tests and in identification of human- 
related and pathogen- related biomarkers that may improve case 
management strategies.
3. To evaluate available biomarker assays to assess their performance 
and potential utility in fever case management in the study areas.
4. To collect social science data on the roles of antimicrobials in fever 
case management for prescribers, local residents and a range of 
stakeholders.
5. To generate data to inform the development of new evidence- based 
fever case management algorithms which may be evaluated in fu-
ture studies.
Study patients are managed by the clinical staff respon-
sible for usual patient care at each study site, according 
to local standard of care. Results of diagnostic tests 
performed at or near the study site are provided to the 
clinical staff as soon as available. Other diagnostic tests 
are performed at internationally recognised reference 
laboratories (see the Specific laboratory assessments 
section).
Recruitment to the study is over a minimum contin-
uous 12- month period at each site to ensure that seasonal 
variations in causes of fever are captured. Blood and 
pharyngeal samples from matched community controls 
enable the calculation of AFs. In addition, control partic-
ipants are surveyed to obtain representative data about 
treatment seeking and medicine use. By combining data 
on causes of fever at study sites with the estimate of the 
proportion of patients with fever seeking care at those 
facilities, the incidence of common infections in the study 
area can be estimated, in order to contribute to efforts to 
define the burden and impact of infectious diseases.24–27 
Social science research is carried out to capture people’s 
responses to febrile illness and the nature of antimicro-
bial use in different settings, the findings from which will 
be used to inform changes in fever case management.
study sites, population and participant selection
The study is being conducted at five sites, all of which 
have little or no published data on causes of fever, and 
where suitably qualified research teams and capacity are 
available. Current study sites include outpatient and inpa-
tient facilities in Bangladesh, Lao People’s Democratic 
Republic (Laos), Malawi, Mozambique and Zimbabwe. 
These sites have been selected because they fulfil the 
aforementioned criteria and because, based on available 
data, there is substantial between- site variation in the 
prevalence of HIV and malaria (table 1).
The study recruits both febrile patients (cases) and 
community controls. Patients are drawn from those who 
present for healthcare at the selected healthcare facili-
ties. All patients aged 2 months and older are eligible for 
enrolment. Patients are recruited if they fulfil all of the 
following criteria:
1. Tympanic or axillary temperature of ≥37.5°C at 
presentation.
2. Not having been hospitalised or having undergone sur-
gery in the previous month.
3. Age ≥2 months (2 months or older).
4. For outpatients, residence (at the time of enrolment) 
within the defined catchment area around the health 
facility.
5. For outpatients aged ≥15 years, absence of symptoms of 
lower respiratory infection and of diarrhoeal diseases 
as defined by
a. Cough and ≥1 of the following: cough productive of 
green/yellow sputum or haemoptysis.
b. Loose stools (≥3) within the previous 24 hours.
6. For outpatients aged ≥2 months to <15 years, absence 
of symptoms of diarrhoeal diseases as defined by ≥3 
loose stools within the previous 24 hours.
7. Willingness and ability to provide demographic and 
clinical information, and clinical samples, at the time 
of enrolment and 28 days later.
8. Provision of written informed consent for adult par-
ticipants; or for children, provision of written consent 
from a parent/guardian and assent from the child (ac-
cording to local regulations and practices at each study 
site).
Social science research is conducted with purposive 
samples of prescribers, medicine sellers and residents in 
the study catchment areas in two countries, as well as with 
stakeholders in the wider public health community.
Participant recruitment began in Zimbabwe in June 
2018, in Malawi in July 2018, in Laos in October 2018 and 
in Mozambique in December 2018; following confirma-
tion of funding, a fifth site is expected to begin in Bangla-
desh in mid-2020.
data and sample collection at the time of patient enrolment 
(day 0)
At patient enrolment, study staff collect basic demo-
graphic data and information on the history of the present 
illness. A study staff clinician performs a physical exam-
ination, including signs that may be used to calculate a 
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severity score (eg, FEAST Paediatric Emergency Triage28 
and Lambaréné Organ Dysfunction Score29 30 for chil-
dren aged <15 years, and quick Sequential Organ Failure 
Assessment31–33 and the ‘universal vital assessment’34 
score for older patients).
Study staff collect pharyngeal swabs and a venous 
blood sample from each participant using standard age- 
based and weight- based thresholds for blood volumes 
obtained.35 In addition, a urine sample is collected from 
patients aged <2 years (using clean- catch methods where 
possible, although this is recognised to be challenging) 
and from older patients who have dysuria, frequent mictu-
rition, suprapubic tenderness or costovertebral angle 
tenderness. Study staff prepare the samples and conduct 
the diagnostic tests described. All other care is provided 
by health facility staff according to local standards.
The FIEBRE study collects clinical samples for two 
purposes: for assays that are of immediate clinical benefit 
to patient care (malaria testing, HIV testing, serum CrAg, 
uLAM, and blood and urine cultures, performed at or near 
the clinical site) and for research purposes (serological 
and nucleic acid assays for pathogen- specific diagnoses, 
assays of immune and endothelial activation markers, and 
RNA analysis in a subset of participants, all of which will 
be done in the future at specialised laboratories).
data and sample collection at the time of patient follow-up 
(day 28)
All patients are asked to return to the study site for 
one follow- up visit 28 days after enrolment (acceptable 
range: 26–48 days, inclusive, after enrolment). At each 
patient’s day 28 follow- up visit, study staff record the clin-
ical outcome of the illness (complete recovery, improve-
ment but incomplete recovery, same as on day 0, worse 
than on day 0, death and loss to follow- up) and obtain 
a convalescent venous blood sample for paired serology 
and biomarker testing. In the event that a patient is lost 
to follow- up or deceased, information is collected from 
other household members where possible.
recruitment, data and sample collection for control 
participants
Interpreting the results of some serological, molecular 
and pharyngeal swab assays requires knowledge of back-
ground prevalence of infection or colonisation in the study 
population. To address this need, ≥600 control partici-
pants are enrolled at each study site. Control participants 
are community members in the study site health facilities’ 
catchment areas, frequency matched 1:2 (or >1:2, where 
logistically feasible) to participating outpatients by month 
of enrolment, age, gender and geographical location of 
residence to the outpatients. No controls are specifically 
recruited for the inpatient population, as inpatients may 
be referred to the participating health facilities from a 
wider geographical area and therefore may be less repre-
sentative of the epidemiology in the study area. Poten-
tial control participants are approached at their place of 
residence by study staff, with assistance from established 
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community health workers, where locally appropriate. 
Controls are recruited two times per month at each site 
and enrolled if they or their parents/guardians provide 
informed consent. The informed consent document and 
process for controls include an explanation that control 
participants are not likely to benefit directly from study 
participation, but that their participation may lead to 
better understanding of febrile illnesses in their commu-
nity and others like it.
Study staff collect basic demographic data from control 
participants. Sample collection and diagnostic testing 
are identical for controls and patients, with three excep-
tions: blood for culture, convalescent sera and urine are 
not collected from controls. Venous blood is drawn from 
control participants using standard age- based and weight- 
based volume guidelines.
healthcare utilisation survey for estimation of incidence of 
infections
In addition, questionnaires are administered to the 
community control participants in order to capture 
representative data about treatment seeking and antimi-
crobial and other medicine use. The control (or health-
care decision- maker if the participant is a child) is asked 
about treatment- seeking practices for each household 
member.24 36 This healthcare utilisation survey provides 
an estimate of the period prevalence of fever, as well as 
the proportion of individuals with fever in the commu-
nity who present to the study enrolment sites for care. 
The fraction of people with fever presenting to a study 
site will be used to estimate the population- based inci-
dence of fever overall and the incidence of specific causes 
of fever in the catchment area of study healthcare facili-
ties.1 24 25 37 38
social science methods
To capture responses to febrile illness and the nature of 
antimicrobial use among prescribers, medicine retailers 
and residents, social scientists use qualitative and quanti-
tative methods derived from medical anthropology. The 
first research phase involves household medicine surveys 
in the study catchment areas, a central feature of which is 
the use of ‘drug bags’ (a collection of physical examples 
of locally available antibiotics) that enable the produc-
tion of qualitative and quantitative data about antibiotic 
recognition, use and access. Details of this method have 
been described elsewhere.39 The second phase is longi-
tudinal ethnographic fieldwork, including participant 
observation and key informant interviews with residents, 
medicine retailers (pharmacists, drug shop workers 
and market vendors) and healthcare workers in clinics 
and hospitals. With prescribers and retailers, qualita-
tive methods are complemented and contextualised by 
the collection of quantitative data about antimicrobial 
prescription, stocks and sales. Alongside ethnography, 
in- depth interviews with stakeholders in the wider public 
health community are conducted to situate local fever 
management and antimicrobial use within broader public 
and global health discourses.
specific laboratory assessments
Laboratory assessments for detection and diagnosis of 
infectious causes of fever focus on those that are treatable 
and/or preventable (table 2). With a few exceptions, the 
same pathogens are sought in samples from all partici-
pants at all sites, including: blood parasites; bacterial, 
mycobacterial and fungal bloodstream infections; typhus 
group and spotted fever group Rickettsia spp; Orientia tsut-
sugamushi; Coxiella burnetii; Leptospira spp; Brucella spp; 
Borrelia spp that cause relapsing fever; Leishmania spp; 
and arboviruses.
Table 2 describes pathogen- based diagnostic tests that 
are performed at or near the point of care at each study 
site; these results are made available in real time to treating 
clinicians for use in patient care decisions. In order to 
standardise diagnostic testing for study results, external 
quality assessment of site results and further diagnostic 
assays for which capacity does not exist currently near the 
research sites are performed at internationally recognised 
reference laboratories (table 2). Cryopreserved samples 
of all microorganisms isolated in culture from blood and 
urine are shipped on dry ice to a reference laboratory 
for confirmation of identification and of antimicrobial 
susceptibility testing to international standards. Partici-
pants’ pharyngeal swabs and blood samples (EDTA whole 
blood, serum, plasma and buffy coat) are aliquoted, stored 
at −80°C and shipped to the collaborating reference labo-
ratories. For each pathogen of interest, all samples from 
all study sites are tested at the same reference laboratory, 
and diagnostic strategies meet internationally accepted 
laboratory- based case definitions.
In addition to diagnostic testing for specific infectious 
agents, a set of assays is carried out to detect host (patient) 
biomarkers that have been identified in previous studies 
as potentially useful in differentiating between bacte-
rial and non- bacterial causes of illness and/or as prog-
nosticators of illness severity. These include C reactive 
protein,40 41 a triggering receptor expressed on myeloid 
cells (sTREM-1),40 42 43 angiopoietin 2,43 44 heparin- inding 
protein40 44 45 and others. The biomarkers sought prior-
itise assays that are most likely to lead to public health 
benefit in fever case management for patient popula-
tions typified by FIEBRE participants. The diagnostic 
and prognostic value of these biomarkers will be assessed 
to determine their utility alone and in combination for 
predicting severe outcomes, using mortality and severity 
scores as endpoints.
sample archive
Informed consent is sought from study participants or 
parents/guardians at recruitment for the future use of 
their biological samples and anonymised data, including 
for the development and evaluation of new diagnostic 
tests, for example, new point- of- care diagnostic tests 
intended to guide the management of febrile patients and 
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assays detecting host transcriptomic signatures of specific 
infections. Residual blood and pharyngeal samples from 
participants are stored and monitored in a central labo-
ratory facility. Access to the samples follows a formal 
process of application and requires approval from both 
the FIEBRE consortium and an independent committee 
including senior scientists as well as lay members.
data sharing
Anonymised data outputs are shared on institutional 
data repositories. All data releases are assigned persistent 
interoperable digital object identifier (DOI) numbers 
(ISO 26324). Nucleic acid sequences and associated 
datasets will be released on relevant data archives (eg, 
EMBL- ENA and GENBANK). Data outputs which reason-
ably, ethically and legally can be shared will be released 
on open- attribution ShareAlike licenses, such as the 
Creative Commons Attribution- ShareAlike V.2.0 Generic 
(CC BY- SA V.2.0).
sample size considerations
Any single pathogen or fever aetiology is likely to be rare 
in the study populations.2 15 16 The prevalence of respira-
tory viruses (eg, influenza and respiratory syncytial virus) 
detected by PCR, and of baseline seropositivity to other 
pathogens, will be compared between cases and controls. 
The prevalence of seropositivity to common causes of 
fever is assumed to be approximately 5% in the general 
population. To identify causes of fever, a sample size of 
600 patients per group will enable estimation of the prev-
alence of an infection whose true prevalence is 5%, with a 
precision of ±1.7% with 95% confidence, and to estimate 
the prevalence of an infection whose true prevalence is 
1%, with a precision of±0.8%. A sample of 600 outpa-
tients and 300 controls will provide >90% power to show 
a significant difference between a prevalence of 12% in 
cases and 5% in controls. Therefore, 600 febrile patients 
are to be enrolled in each of four analysis groups (children 
aged ≥2 months to <15 years, and patients aged ≥15 years, 
with stratified enrolment so that within each of the two 
age groups, approximately half are inpatients and half are 
outpatients), for a total of 2400 patients per site, plus 300 
controls in each of the two age groups at each site (total 
600). Site- specific recruitment strategies allow enrolment 
of a representative sample of patients presenting over 
the course of the study at each site. The social science 
research will involve 100–150 participants per site, with 
the sample size determined by data saturation.
data analysis plan for primary outcomes
To determine the treatable and/or preventable causes of 
fever in the study population, the AF will be calculated 
for each pathogen or group of pathogens. This will be 
done separately for each site and age stratum. For each 
group of patients, the OR for the association between 
each pathogen and fever will be calculated, using logistic 
regression, by comparing cases and controls. Strata based 
on geographical location and season will be defined at 
each site, and the analysis will be adjusted for age, sex 
and stratum. A weighted analysis will be performed to 
reflect the relative frequency of fevers that present in 
each season. For pathogen A, the AF (AFA) will then be 
calculated as AFA=pA(1- ORA), where pA is the proportion 
of cases with pathogen A, and ORA is the OR for the asso-
ciation between presence of pathogen A and being a case. 
CIs will be calculated using bootstrap methods.
To determine the prevalence and spectrum of antimi-
crobial resistance among bacterial pathogens identified 
in the study, at each site, the proportion of bacterial 
pathogens with antimicrobial resistance defined by stan-
dardised criteria will be calculated. The proportion of 
common organisms demonstrating resistance to a stan-
dard panel of antimicrobials will be reported.
To generate data on incidence of specific infections 
among study participants and contribute to estimates 
of disease burden, for an area with known or estimated 
population size, responses to the healthcare utilisation 
survey questions will be used to estimate r, the propor-
tion of fevers for which treatment was sought at the study 
facility. The total number of cases seen at the study site 
from the defined population will be multiplied by 1/r to 
obtain the total cases in a year from the defined popula-
tion. This will be divided by the size of the population to 
estimate incidence. Incidence of fever caused by specific 
pathogens will be calculated by multiplying the incidence 
by the AF for that pathogen.
To assess the performance and potential utility of 
biomarker assays to guide fever case management in the 
study areas, each biomarker and biomarker combina-
tions will be compared with mortality and severity scores 
calculated using clinical data and with pathogen- specific 
diagnoses.
To generate data to support the development of new 
fever case management algorithms which may be evalu-
ated in future studies, the association between the pres-
ence of pathogens with predefined clinical and other 
variables will be examined, and social science research 
findings will shape recommendations. Social science data 
will be analysed iteratively as themes emerge and are 
followed up during ethnographic fieldwork. Patterns in 
the data will be interrogated in consultation with wider 
social theory, building on our reviews and analyses of ‘the 
social’ in fever case management46 and antimicrobial 
resistance.47
Ethics and dissemination
Ethics approval of the study protocol was obtained from all 
relevant institutional and national committees (table 1). 
Written informed consent was obtained from all partici-
pants, or their parents/guardians, for study participation 
and for future use of biological samples. No individual 
participant identities will be used in any reports or publi-
cations resulting from the study.
Before beginning study activities at each site, meetings 
are held with community leaders and representatives of 
the public, and with staff at participating health facilities, 
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to provide information about the aims of the study and 
the methods to be used. When final results are available, 
feedback and dissemination meetings will be held at each 
site both for healthcare staff and for the communities 
who participated in the study.
Investigators and study staff engage with national and 
international networks to ensure that researchers, public 
health advocates and policy makers at various levels are 
aware of the study. The study protocol, standard oper-
ating procedures, data collection tools and other study 
documents are freely available on request from coinves-
tigators and at the FIEBRE study website (DOI: https:// 
doi. org/ 10. 17037/ PUBS. 04652739). Press releases and 
website updates publicise study progress. Study results 
will be prepared for publication in open- access peer- 
reviewed journals, and presented at national and inter-
national scientific conferences as soon as possible after 
study completion.
Patient and public involvement
Patients were not directly involved in the development 
of the research questions, the design of this study or the 
conduct of the study. The FIEBRE study does include 
substantial interaction with communities in the study 
areas to promote awareness and acceptance of patient 
recruitment at health facilities, and to encourage partici-
pation as community controls and in social science activ-
ities. Study results will be disseminated in participating 
communities at each site through the collaborating 
research group’s public engagement teams and commu-
nity advisory groups, using locally appropriate strategies. 
Community feedback, as well as findings from social 
science research, will be incorporated into future recom-
mendations for improved fever case management.
dIsCussIon
The FIEBRE study is designed to investigate causes of 
febrile illness and antimicrobial resistance at multiple sites 
in Africa and Asia, where currently there is little evidence 
and very limited diagnostic capacity to guide fever case 
management. FIEBRE focuses on detecting infections 
that are treatable (eg, with specific antimicrobials) and/
or preventable (eg, with vaccination or vector- control 
approaches). Across all sites, the study uses a common 
design, selection criteria, case definitions, laboratory 
procedures and analysis plan. This harmonised approach 
will generate reliable and comparable data that can 
contribute to updated recommendations on the clinical 
management and prevention of febrile illnesses, adapted 
to local contexts. In addition, due to the inclusion of 
community control participants, the study will provide 
data to support reliable estimates of the incidence and, in 
turn, burden of disease.
This study provides a unique opportunity to collect and 
store biomedical samples with data from a large and well- 
characterised group of febrile patients and controls from 
representative settings in Africa and Asia. The samples 
will be useful for identification of novel diagnostic targets 
and to guide prioritisation for the development and eval-
uation of new point- of- care diagnostic tests intended 
to guide the management of febrile patients. New tests 
could include those that predict severity of illness, detect 
specific infections, and/or differentiate between bacterial 
and viral infections to help guide antimicrobial therapy, 
identified as high priority at a WHO meeting of experts 
convened in 2015.21
It is anticipated that data generated by FIEBRE on 
causes of febrile illness and antimicrobial susceptibility, 
alongside the social science work on the role of antimi-
crobials in fever case management, will be incorporated 
into new diagnostic strategies and case management 
guidelines which can then be evaluated and optimised in 
various contexts.
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